Tumblelog by Soup.io
Newer posts are loading.
You are at the newest post.
Click here to check if anything new just came in.

October 19 2017

mr-absentia

July 09 2017

mr-absentia
G20,気候変動で「パリ協定」離脱の米国対象とせず合意。貿易では「反保護主義」で一致。これも対米。トランプ政権下の米国が世界の潮流から離脱鮮明に。安倍首相は「反トランプ」の欧州主導に沿う。こんな事例もこれまで無かったろう
— @magosaki_ukeru on Twitter

May 16 2017

mr-absentia

アメリカの通商政策に対する世界の懸念 - Pars Today

“トランプ大統領はアメリカへの外国製品の流入を妨げるために関税率を上げ、資本家や富裕層などの人々に対する税率を下げることを支持しています。トランプ大統領の目的は、投資家に対するアメリカ国内への投資の奨励であり、アメリカの雇用機会を増やすことです。また、他国に貿易協定を見直す協議を求めています。また、大統領令を発したように、すべての二国間、あるいは多国間の通商協定を見直すよう要求しています。

一方、このトランプ大統領のアプローチは、G7の先進国や、G20・20カ国の新興国の懸念を引き起こしています。トランプ大統領の新たな通商政策に注目すると、アメリカでのこれらの国の輸入品の最終価格は、大幅に上昇し、これらの国のアメリカ市場における競争力は著しく低下することになります。この問題により、アメリカの主要な経済相手国となっている国は、トランプ政権の通商政策の見直しを求めており、またドイツなどの一部の国は、この問題に関するトランプ大統領の公約が実施されれば、WTO世界貿易機関に訴えるとしています。

明らかに、トランプ大統領の輸入制限の目的は、アメリカの輸入額の減少のみならず、雇用の創出のために、アメリカ国内に投資し、工場を建てることへの、アメリカ企業に対する奨励です、こうした中、もしアメリカが保護主義政策を真剣に追求するのであれば、G7のみならず、G20の反発に直面することになります。この場合、グローバル化のプロセスは著しく後退することになります”

October 27 2014

mr-absentia

September 21 2014

mr-absentia

May 14 2014

mr-absentia

March 24 2014

mr-absentia

March 20 2014

mr-absentia
mr-absentia

March 19 2014

mr-absentia

June 28 2013

mr-absentia
The government of leftist President Rafael Correa came up with an angry response on Thursday after an influential US senator said he would use his leverage over trade issues to cut preferential treatment of Ecuadoran goods at the US market, should Ecuador grant political asylum to Snowden. ‘Ecuador will not accept pressures or threats from anyone, and it does not traffic in its values or allow them to be subjugated to mercantile interests,’ government spokesman Fernando Alvarado said at a news conference. He added that Ecuador is willing to allocate $23 million annually, an equivalent of the sum that it gained from the benefits, to fund human rights training in the US. It will ‘avoid violations of privacy, torture and other actions that are denigrating to humanity,’ Alvarado said.
Ecuador snubs US trade ‘blackmail’ over Snowden, offers human rights training (RT News, Jun. 28 2013)
mr-absentia

[Senator Robert] Menendez [who heads the Foreign Relations Committee in the Senate] said he would lead the effort to prevent the renewal of Ecuador's duty-free access to US markets under the Generalized System of Preferences program. He also said he would block renewal of the Andean Trade Promotion and Drug Eradication Act (ATPDEA). Both programs expire at the end of next month.

The major commodities of Ecuador’s export to the US are crude oil, cut flowers, fruits and vegetables, shrimp and prawns. Duty-free access to US markets is supporting roughly 400,000 jobs in the country of 14 million people.

Ecuador is the last remaining recipient of the ATPDEA, which used to include Bolivia, Colombia and Peru in the past and was not expected to be renewed for Ecuador even before Snowden came up with his revelations of the US phone and internet surveillance programs.

The country has been lobbying the Obama administration to include additional goods under the Generalized System of Preferences program to soften the blow from the cancellation.”

'World order unjust and immoral!' Ecuador’s Correa rips into Snowden coverage (RT News, Jun. 27 2013)


“The US announced on Thursday [Jun. 27] that it is reviewing whether to suspend favorable trade benefits with Ecuador, only a few hours after that country’s foreign minister preemptively renounced them. The Ecuadorian government pulled out of its trade pact, which involves preferential customs tariff rights, claiming it had become an instrument of ‘blackmail’ as relations with the US have been strained over reports the country is considering a political asylum bid from Edward Snowden.”

NSA leak fallout: LIVE UPDATES (RT USA)

June 27 2013

mr-absentia

21:14 GMT: Senator Robert Menendez, the chairman of the Foreign Relations Committee, said on Wednesday that if Ecuador grants Snowden asylum he will ‘make sure there is no chance for renewal’ of trade pacts with the South American nation. Menendez pledged to end Ecuador’s preferential trade access with the US, while reiterating a call on Moscow to turn Snowden over.”NSA leak fallout: LIVE UPDATES

“‘Ecuador Risks Trade Problems With U.S. if It Grants Asylum to Snowden’ - but it would be a UN violation to act so” — @wikileaks

May 21 2012

mr-absentia

【Twitter】 野田総理@G8

  • @kawauchihiroshi: キャンプデービットのG8。野田内閣の昨年9月の基本方針では「経済成長と財政再建の両立」と、経済成長が先になっていたが、G8で総理は「財政再建と経済成長の両立」と、財政再建を先にしている。どちらが先か、非常に重要。基本方針(閣議決定)違反の発言である。

  • @kawauchihiroshi: G8で野田総理は、「成長の原動力たる自由貿易」と言う言葉も使っている。彼は「自由貿易」という言葉の定義を知っているのだろうか?GATT24条に「実質的に全ての物品の関税撤廃」とあるが「実質的に全ての物品」とは「9割の物品」という解釈。TPPは10割の物品であり、自由貿易ではない。

May 01 2012

mr-absentia

【IRIB】 イランのサフラン

February 16 2012

mr-absentia

About the Novartis Drop the Case Campaign (msfaccess.org)

Why India is the ‘pharmacy of the developing world’

India is often called the ‘pharmacy of the developing world’ because it produces affordable generic versions of medicines that are used the world over. More than 80% of the antiretroviral medicines (ARVs) used by MSF in its HIV/AIDS programmes come from producers of generics based in India, just as 80% of the ARVs purchased with donor funds globally come from India. MSF also relies on Indian generics for malaria and tuberculosis treatments.

India became the key producer of affordable medicines because until 2005, the country did not grant patents on medicines, allowing generic manufacturers to freely produce more affordable versions of medicines patented elsewhere. Fierce competition among producers drove prices down dramatically – whereas ARVs for one person per year cost US$10,000 in 2000, today, they cost just less than one percent of that figure.

India starts granting – and rejecting – patents

India had to start granting patents for medicines in 2005 because of its obligations as a member of the World Trade Organization. This means that price-busting competition between generic and originator drug producers will be blocked for drugs that receive patents – for example for several newer medicines to treat HIV/AIDS.

When designing its patent law, however, India decided that only drugs that show an improved therapeutic effect over existing ones deserve patents. This part of the law – ‘Section 3d’ – intends to prevent companies from continually extending their 20-year drug patents by making minor changes or improvements – a process called ‘evergreening.’ Along these lines, the Indian patent examiner in 2006 rejected the patent that Swiss pharmaceutical company Novartis sought for the leukemia drug imatinib mesylate (marketed as Glivec), because it was based on a compound that already existed.

Novartis takes the Indian government to court

In response to its drug patent being rejected, Novartis took the Indian government to court in 2006, not only challenging the rejection of its patent, but also the part of India’s law, Section 3d, that formed the basis of the decision. If Section 3d were overturned, it would mean patenting would become much more widespread in India, severely limiting the production of more affordable generics.
Older posts are this way If this message doesn't go away, click anywhere on the page to continue loading posts.
Could not load more posts
Maybe Soup is currently being updated? I'll try again automatically in a few seconds...
Just a second, loading more posts...
You've reached the end.

Don't be the product, buy the product!

Schweinderl